Expert consensus on interstitial lung disease associated with systemic autoimmune diseases. Executive summary

Area of Science:

• Rheumatology
• Pulmonology
• Internal Medicine

Background:

• Interstitial lung disease (ILD) frequently complicates systemic autoimmune diseases (SAD).
• Optimal management of SAD-associated ILD is challenging due to disease complexity and limited evidence, leading to guideline variability.
• Early intervention is crucial for patient survival and quality of life.

Purpose of the Study:

• To develop expert consensus recommendations for the screening, diagnosis, treatment, and follow-up of ILD in patients with SAD.
• To provide guidance for managing ILD in specific systemic autoimmune diseases.

Main Methods:

• A group of Systemic Autoimmune Disease (SAD) experts convened to formulate recommendations.
• Recommendations were based on a review of the latest evidence, clinical experience, and a survey of specialist practices.
• Included diseases: systemic sclerosis, Sjögren's disease, idiopathic inflammatory myopathy, ANCA-associated vasculitis, sarcoidosis, and systemic lupus erythematosus.

Main Results:

• The article presents comprehensive recommendations covering all stages of ILD management in SAD.
• Specific guidance is provided for the included systemic autoimmune diseases.
• The recommendations aim to standardize and improve the care of patients with SAD-associated ILD.

Conclusions:

• Standardized screening, diagnosis, and treatment protocols for ILD in SAD are essential.
• Expert consensus recommendations can help bridge evidence gaps and reduce management variability.
• Implementing these guidelines may improve patient outcomes and survival in SAD-associated ILD.